Danaher DHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $1.8B+11.5% | $2.03B+8.8% | $1.8B+8.8% | $1.85B+8.0% | $1.61B+5.8% | |
| Diagnostics | $2.42B-1.3% | $2.72B+3.1% | $2.46B+4.2% | $2.31B+2.2% | $2.45B-3.1% | |
| Life Sciences | $1.74B+3.4% | $2.09B+2.6% | $1.79B+0.6% | $1.78B+0.4% | $1.68B-3.7% | |
| Segment Reporting, Other Segment Item, Amount by Business | ||||||
| Biotechnology | $989M+7.0% | $1.22B+10.3% | $1.09B+8.1% | $1.05B+5.1% | $924M-1.6% | |
| Diagnostics | $1.59B+0.6% | $1.85B+1.8% | $1.63B+1.9% | $1.61B+3.3% | $1.58B+2.0% | |
| Life Sciences | $1.31B+2.1% | $1.54B+4.9% | $1.37B+2.6% | $1.39B+2.4% | $1.29B-3.5% | |
| Operating Income (Loss) by Business | ||||||
| Biotechnology | $534M+21.1% | $540M+6.3% | $352M-9.7% | $531M+14.9% | $441M+35.7% | |
| Diagnostics | $674M-6.1% | $713M+14.3% | $665M+8.1% | $554M-0.4% | $718M-13.5% | |
| Life Sciences | $225M+11.9% | $336M-10.6% | $222M+534% | -$239M-203% | $201M-14.5% | |
| Identifiable assets by Business | ||||||
| Biotechnology | $36.7B+1.6% | $37.34B+7.9% | $37.3B— | $37.56B— | $36.12B— | |
| Diagnostics | $14.66B— | $14.75B+3.8% | —— | —— | —— | |
| Life Sciences | $22.87B— | $23.11B-0.4% | —— | —— | —— | |
| Depreciation by Business | ||||||
| Biotechnology | $40M+17.6% | $39M+2.6% | $38M+5.6% | $38M+8.6% | $34M-19.0% | |
| Diagnostics | $102M+2.0% | $106M+3.9% | $101M+6.3% | $100M0.0% | $100M+3.1% | |
| Life Sciences | $48M+6.7% | $48M+9.1% | $47M+6.8% | $45M+9.8% | $45M+18.4% | |
| Capital expenditures, gross by Business | ||||||
| Biotechnology | $64M-21.0% | $115M-1.7% | $94M-19.7% | $80M-27.9% | $81M-20.6% | |
| Diagnostics | $144M+25.2% | $195M+16.1% | $157M+21.7% | $125M-0.8% | $115M-9.4% | |
| Life Sciences | $27M-43.8% | $57M-75.1% | $40M-23.1% | $41M-18.0% | $48M-20.0% | |
| Intangible Amortization by Business | ||||||
| Biotechnology | $234M+9.9% | $230M+8.0% | $231M+6.0% | $228M+6.5% | $213M-2.3% | |
| Diagnostics | $48M0.0% | $47M0.0% | $48M-2.0% | $48M0.0% | $48M0.0% | |
| Life Sciences | $152M+2.0% | $151M+2.0% | $154M+4.8% | $150M+7.1% | $149M+5.7% | |
| Goodwill by Business | ||||||
| Biotechnology | $23B+3.1% | $23.31B+8.8% | $23.15B+2.7% | $23.14B+5.8% | $22.32B+1.9% | |
| Diagnostics | $6.96B+1.8% | $6.98B+3.4% | $6.97B+0.5% | $6.97B+2.0% | $6.84B-0.1% | |
| Life Sciences | $12.81B+2.4% | $12.86B+4.5% | $12.84B+1.0% | $12.88B+6.5% | $12.51B+3.3% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $920M-0.5% | $1.51B+5.7% | $1.04B+1.5% | $966M-8.3% | $925M-7.6% | |
| Recurring revenue | $5.03B+4.5% | $5.32B+4.3% | $5.02B+5.0% | $4.97B+6.0% | $4.82B+0.4% | |
| Sales by Geography | ||||||
| High-growth markets | $1.62B+5.7% | $2.03B+5.9% | $1.76B+2.2% | $1.7B+0.1% | $1.54B0.0% | |
| North America | $2.48B-4.0% | $2.76B-0.6% | $2.58B+5.0% | $2.44B+0.2% | $2.58B-1.9% | |
| Other developed markets | $284M+2.2% | $364M+1.4% | $316M+5.7% | $294M+0.7% | $278M-8.3% | |
| Western Europe | $1.57B+16.4% | $1.69B+13.3% | $1.4B+5.8% | $1.51B+14.1% | $1.34B+1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
